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ABSTRACT 
 
Cecily Robin Smith: Underuse of Oral Anticoagulation Therapy in Older Adults with Atrial 
Fibrillation After Stroke 
(Under the direction of Carrie Palmer) 
Background and Purpose: There was an identified underuse of oral anticoagulation 
(OAC) among individuals who were over the age of 65 with atrial fibrillation (AF).  The purpose 
of this DNP project was to identify patients aged 65 or older with a diagnosis of AF and a 
cerebral vascular accident (CVA) or transient ischemic attack (TIA), not on current OAC to 
determine if a prescription was provided to them at time of discharge from the hospital or during 
a post-hospitalization follow up appointment with their primary care or cardiology provider. 
Method: A retrospective medical record review was used over a three-month period in 
2016 to determine clinical practice of providers prescribing OAC to patient ages 65 and older 
with AF and known stroke or TIA diagnosis.  An evidence-based clinical decision support 
algorithm for the treatment of those with AF who had a CVA or TIA was implemented over a 
12-week period at a large, independent hospital using the ACE Star Model of Knowledge 
Transformation, a framework for putting evidence-based processes into operation.  The risk for 
stroke and bleeding was calculated using the CHA2DS2-VASc score and HAS-BLED tools.  
Following the implementation period, the same three-month span was selected in 2017 for a 
retrospective record review to determine the effectiveness of the intervention. 
Results: A total of 27 patients were included in this project.  The number of eligible 
patients who were offered prescriptions for OAC increased from 87% in 2016 to 100% in 2017.
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Conclusion: The intervention resulted in the desired change towards evidence-based 
practice among providers.  Following implementation of the project discharging providers not 
only included neurology’s recommendations in their discharge notes, but also provided 
prescriptions to eligible patients rather than leaving it to the patient’s primary care provider to 
initiate. 
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CHAPTER1: Introduction 
Atrial fibrillation (AF) is the most common cardiac arrhythmia affecting 5% of 
individuals over the age of 65.  Atrial fibrillation carries a five-fold higher risk for an ischemic 
stroke compared to adults without the diagnosis.  As individuals with AF age, their risk for a 
stroke increases, making AF the single most probable cause of ischemic strokes among older 
adults (Sellers & Newby, 2011).  The number of individuals with AF is expected to increase due 
to the aging baby boomer population thus increasing the number of individuals at risk for having 
a stroke, specifically an embolic stroke (Khan, Huang & Datta, 2016).  The mortality rate 
associated with AF-related strokes is higher than those not related to AF, and there is greater 
disability, longer hospitalizations, and poorer functional outcomes in AF-related strokes (Lip, 
2013; Padjen, Jovanovic, Leys, & Beslac-Bumbasirevic, 2013).  The increased risk for stroke is 
similar with either paroxysmal AF or sustained AF (Meschia et al., 2014). 
Stroke in the setting of AF creates a high suspicion for cardioembolic etiology. Age is 
also an associated risk for an embolic stroke.  Oral anticoagulation therapy (OAC) has been 
found to be highly effective in preventing thromboembolism, thus reducing stroke risk in 
individuals with AF and extending the lives of many (Kirchhof et al., 2016).  According to the 
American College of Cardiology/American Heart Association/Heart Rhythm Society 
(ACC/AHA/HRS) guideline (January et al., 2014), the CHA2DS2-VASc score is recommended 
to determine stroke risk in patients with nonvalvular atrial fibrillation (NVAF) (Table 1).  A 
CHA2 DS2-VASc score of > 2 is considered a high stroke risk score and initiating OAC is 
recommended (Odum, Cochran, Aistrope, & Snella 2012).
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The CHADS2 (Congestive heart failure, Hypertension, Age >75 years, Diabetes mellitus 
previous Stroke/transient ischemic attack (TIA) is another risk stratification score.  When the 
CHADS2 and the CHA2 DS2-VASc are compared, both predict an outcome of an acute stroke; 
however, the CHA2 DS2-VASc score predicts a higher percentage of high stroke risk scores using 
more common stroke risk factors and identifies true low risk patients (Lane & Lip, 2012).  
Therefore, the CHA2 DS2-VASc tool increases the number of patients with AF who are eligible 
for OAC (Padjen et al., 2013). 
Nonvalvular AF is defined in the ACC/AHA/Heart Rhythm Society (HRS) 2014 
guidelines as AF in the absence of the following: rheumatic mitral stenosis, mechanical or bio 
prosthetic heart valve, or mitral valve repair (January et al., 2014).  The introduction of direct 
oral anticoagulants (DOACs) has expanded the therapeutic options for primary and secondary 
stroke prevention in patients with nonvalvular AF. 
With the use of OAC there also comes an increased risk for bleeding and in some cases 
death.  The HAS-BLED score (Table 1) is a simple bleeding score that was developed and first 
validated by the EuroHeart survey and then in multiple independent populations (Lip, 2012).  
The HAS-BLED score ranges from 0 to 9, with scores of ≥3 indicating a high risk of bleeding. 
The HAS-BLED score should not be used to exclude patients from OAC, rather individuals with 
a HAS-BLED score of 2 or higher should be closely monitor for bleeding following the initiation 
of OAC. Risk factors for bleeding that are correctable should be addressed and modified where 
possible (Palomaki et al., 2012). 
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Table 1 
 
Stroke Risk Score and Bleeding Risk Score 
CHA2DS2-VASc Score HAS-BLED Score 
Congestive heart failure/Left 
ventricular dysfunction 
 
1 Hypertension 1 
Hypertension 1 Abnormal renal or liver 
function 
 
1 or 2 
Age ≥ 75 years 2 Stroke 1 
Diabetes mellitus 1 Bleeding tendency of 
predisposition 
 
1 
Previous Stroke/transient 
ischemic 
attack/Thromboembolism 
 
2 Labile International Normalized 
Ratio (INR) (if on warfarin) 
1 
Vascular disease (prior 
myocardial infarction, 
peripheral artery disease, or 
aortic plaque) 
 
1 Age >65 1 
Age 65-74 years 1 Drugs 
(aspirin or NSAIDS or alcohol 
excess/abuse) 
1 
Sex category (female sex) 1   
Maximum score 9 Maximum Score 9 
Table 1. Stroke risk and bleeding risk scores.  Adapted from "Predicting the outcomes of acute 
ischaemic stroke in atrial fibrillation:  The role of baseline CHADS2, CHA2DS2-VASc and 
HAS-BLED score values" by Padjen et al., 2013, ActaCardiologica, 68(6), 590-596. Copyright 
2013 by ActaCardiologica. 
 
There are now several different OAC options for individuals with nonvalvular AF who 
score a CHA2 DS2-VASc score of > 2 and have low hemorrhagic complications.  Vitamin K 
antagonists (VKA), warfarin, with a goal INR range of 2-3, and the direct oral anticoagulants 
(DOACs) dabigatran, rivaroxaban, apixaban, and edoxaban have been approved for prevention 
of CVA in individuals with nonvalvular AF (Meschia et al., 2014).  All available anticoagulants 
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have been shown to prevent stroke effectively.  One advantage to the DOACs is a decreased risk 
for intracerebral hemorrhage (ICH).  Another advantage is the shorter half-life of 5-17 hours 
compared to 20-60 hours with warfarin (Ansell, 2016; Moroti & Goldstein, 2016; Verheugt, 
2013).  Oral anticoagulant therapy is superior to antiplatelet therapy when providing prevention 
of stroke in the setting of AF (Baker, Wilsmore, & Narasimhan, 2016). 
Reversal agents are available or under development for VKA and DOACs. Vitamin K 
will reverse VKA-induced coagulopathy, but it requires 12-24 hours for results to be seen.  Fresh 
frozen plasma (FFP) and prothrombin complex concentrates can be used to reverse VKA-related 
bleeding (Ansell, 2016).  Idarucizumab is the approved reversal agent for the direct thrombin 
inhibitors, dabigatran.  Dexanetalfa is a reversal agent underdevelopment for the factor Xa 
inhibitors, rivaroxaban, apixaban, and edoxaban.  Ciraparantag is a reversal agent 
underdevelopment for direct thrombin inhibitors and factor Xa inhibitors (Ansell, 2016).  An 
individual experiencing non-urgent bleed such as gastrointestinal bleed that responds to fluid 
resuscitation or need for emergent surgery can simply discontinue the DOAC which will permit 
rapid reversal.  Patients experiencing a major bleeding event such as trauma, overdose, or need 
for urgent intervention while on DOACs should receive fluid resuscitation, packed red blood cell 
transfusion, and platelet transfusion.  Hemodialysis may reverse dabigatran.  For an individual 
that has ingested a DOAC within two to three hours prior to the time of treatment, gastric lavage 
with activated charcoal is recommended (Ansell, 2016).  Providers also need to consider an 
individual’s kidney function when initiating anticoagulation therapy; DOACs are metabolized 
through the kidneys and those with poor kidney function have an increased risk of anticoagulant 
associated bleeding (Morotti & Goldstein,  2016). 
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Statement of the Problem 
Oral anticoagulation therapy has been shown to reduce stroke risk by 64% in individuals 
with AF (Meschia et al., 2014).  Unfortunately, there is an underuse of OAC by providers caring 
for individuals over the age of 65 with AF, particularly those perceived to be at risk for falls 
(Donzé et al., 2012; Jacobs, Billett, Freeman, Dinglas, & Jumaquio, 2009; Khan, Huang, & 
Datta, 2016).  Studies have demonstrated only 55% of individuals who have AF and meet the 
criteria are being prescribed OAC (Ogilvie, Newton, Welner, Cowell, & Gregory, 2010).  The 
impact of a stroke affects not only the individual, but their family related to costs as well as the 
healthcare system as a whole related to the number of resources this stroke victim will likely 
utilize.  The indirect costs include productivity loss due to a premature death, disability, and the 
informal caregiving by family members.   
Purpose of the Project 
The purpose of the practice change DNP project is to increase the number of healthcare 
providers prescribing OAC in the outpatient setting among individuals who are age 65 or older, 
have a known history of AF, and a recent diagnosis of cerebral vascular accident (CVA) or 
transient ischemic attack (TIA).  The role of OAC management typically falls to the patient’s 
primary care provider or cardiology provider.  By utilizing stroke and bleeding risk stratification 
schemes the decision to initiate OAC is simplified.  Stroke prevention is key due to the increased 
risk of reoccurring strokes in individuals with AF and history of a TIA and/or CVA (Esenwa & 
Gutierrez, 2015). 
Clinical Practice Question 
Why do providers inconsistently prescribe OAC to patients with AF who are at risk for 
falls despite guideline recommendations?  Several studies provide evidence that “fall risk” is not 
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a contraindication to OAC (Banerjee, Clementy, Haguenoer, Fauchier, & Lip, 2014; Donzé et. al, 
2012; Garwood & Corbett, 2008; Sellers & Newby, 2011) and use would improve patient 
outcomes by decreasing the risk for embolic stroke or ischemic events.  Providers may be 
hesitant to initiate OAC in individuals who are considered at risk for falls due to the possible 
hemorrhagic complications, including ICH following a fall in the presence of OAC, lack of 
availability to reversal agents for some of the newer DOACs, or a previous patient experience 
with a poor outcome (Banerjee et al., 2014;Gattellari, Worthington, Zwar, & Middleton, 2008; 
Man-Son-Hing, Nichol, & Lau, 1999).  According to Man-Son-Hing et al., (1999) an individual 
taking warfarin would have to fall 295 times in one year before the risk of being on the 
anticoagulant would outweigh the benefits.  Providers should consider the risk of stroke 
compared to the risk of bleeding when recommending OAC and referring to a stroke and bleed 
risk model like the CHA2DS2-VASc score of > 2 and a HAS-BLED score of > 2 (Lane & Lip, 
2012; Padjen et al., 2014). 
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CHAPTER 2: Review of Literature 
A review of the literature identifies a range of factors associated with the underuse of 
OAC in older adults with AF.  For this review, only studies focusing on AF and the use of OAC 
in individuals 65 and older were included due to existing gaps in the literature surrounding this 
topic.  Two online databases, CINAHL and PubMed, were searched for research articles 
published after 2006 using the following key search terms: anticoagulation, warfarin, aspirin 
CHADS2 score, CHA2DS2 -VASc score, HAS-BLED, elderly, falls, older persons, atrial 
fibrillation, bleeding, physical activity, education, stroke, use, fall risk, and shared decision 
making.  Articles containing the following inclusion criteria were selected: (a) both AF and OAC 
in adults 65 years and older; (b) the studies collected included randomized controlled trials , 
retrospective analyses, observational studies, longitudinal study designs, meta-analysis, 
qualitative analysis, focus groups or surveys; (c) the findings included AF and OAC; fall risk and 
OAC; incident of bleeding and AF; CHADS2 score and AF; CHA2DS2 -VASc score and AF; 
HAS-BLED and AF; and the effects of using/not utilizing OAC in the setting of AF; (d) date of 
publication span from 2006-2016; (e) published in English; (f) included all races; and (g) 
included both female and male human subjects.  Studies containing the following exclusion 
criteria were not used: (a) non-English articles; (b) articles published before 2006; (c) articles not 
related to OAC or AF in the older adult.  Using the above criteria,167 journal articles were 
obtained for review.  Additional references were obtained through review of references from 
articles obtained and practice guidelines.  Three practice guidelines and 20 articles were
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reviewed.  Eleven studies did not meet inclusion criteria leaving nine articles and three practice 
guidelines for this review. 
Nine studies and three practice guidelines published from 2007-2016 were identified.  
Two studies took place in the United States (Aakreet al., 2014; Jacobs, Billet, Freeman, Dinglas, 
& Jumaquio 2009); one study took place in Saudi Arabia (Al-Turaiki et al., 2016); one in Serbia 
(Padjen et al., 2013); one in Scotland (Abdul-Rahim, Wong, McAlpine, Young, & Quinn, 2014); 
two in Australia (Baker, Wilsmore, & Narasimhan, 2015; Gattellari, Worthington, Zwar, & 
Middleton, 2007); one in France (Banerjee, Clementy, Haguenoer, Fauchier, & Lip 2014);and 
one study took place in Europe, Japan, North America, China and intercontinental (Hart, Pearce, 
& Aguilar, 2007).  Two of the three practice guidelines were from the United States (Furieet al., 
2012; January et al., 2014), and the third was from Europe (Kirchhof et al., 2016).  Two studies 
were cross sectional (Abdul-Rahimet al., 2014; Al-Turaiki et al., 2016), one study was 
longitudinal, (Aakre, et al., 2014), four studies were retrospective (Baker et al., 2015; Banerjee et 
al., 2014; Jacobs, 2009; Padjen et al., 2013), one study was a survey (Gattellari et al., 2007), and 
one study was a systematic review with meta-analysis (Hart et al., 2007).  Three clinical practice 
guidelines were also reviewed (January et al., 2014;  Kirchhof et al., 2017; Meschia et al., 2014). 
Six of the nine studies had large numbers of subjects increasing their strength and 
generalizability (Aakre et al., 2014; Abdul-Rahim et al., 2014; Baker et al., 2015; Banerjee et al., 
2014; Gattellari et al., 2007; Hart et al., 2007).  The subjects in the study by Gattellari et al. 
(2007) were family physicians and addressed the psychological barriers to prescribing OAC.  In 
one study subjects were obtained from a single registry where risk factors may have been under 
diagnosed (Aakre et al., 2014).  Another study had a small sample size in a single site register 
based observational setting (Padjen et al., 2013).  The subjects were from a single center and 
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there was no discernment between non-valvular and valvular AF in the medical records (Padjen 
et al., 2013).  The meta-analysis was the largest summarizing study of its kind evaluating the 
effects of antithrombotic therapy in stroke prevention among those with non-valvular AF (Hart et 
al., 2007).  The meta-analysis included 29 RCTs and nine double-blind trials.  Methodological 
features varied in the meta-analysis.  
Sample Characteristics 
 A total of 42,361 subjects participated in these eight studies that support practice 
guidelines using OAC in individuals that had AF and had been screened by a stroke risk model 
and bleeding model (Aakre et al., 2014; Abdul-Rahimet al., 2014; Al-Turaiki et al., 2016; Baker 
et al., 2007; Banerjee et al., 2014; Hart et al., 2007; Jacobs et al., 2007; Padjen et al., 2013). 
Abdul-Rahim et al. (2014), Al-Turaiki et al. (2016), Banerjee et al. (2014), and Jacobs et al. 
(2007) were the only four studies that reported the sex of the participants.  A total of 596 
physician subjects participated in survey reporting AF management (Gattellari et al., 2007). 
A cross sectional study by Abdul-Rahim et al. (2014) reported 6736 men with chronic 
AF, aged 65 years and older and 8001 women aged 65 years and older with AF.  The meta-
analysis by Hart et al. (2007) consisted of 28,044 participants with AF with average age 71 
years.  Some of the trials in the Hart et al. (2007) meta-analysis included individuals with 
previous stroke or TIA.  Lastly, there were three clinical practice guidelines included that 
recommended the use of OAC for management of stroke prevention in individuals with AF but 
did not have any participants (January et al., 2014; Kirchhof et al., 2017; Meschia et al., 2014) 
Risk Assessment 
Eight of the nine studies (Aakreet al., 2014; Abdul-Rahimet al., 2014; Al-Turaiki et al., 
2016; Baker et al, 2015; Banerjee et al., 2014; Hart et al., 2007; Jacobs et al., 2007; & Padjen et 
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al., 2013;) used a CHADS2, or a CHA2DS2-VASc score and five of the nine studies used HAS-
BLED to evaluate participants’ risk of a stroke and bleeding (Abdul-Rahim et al., 2014; Al-
Turaiki et al., 2016; Baker et al., 2015; Banerjee et al., 2014; & Padjen et al., 2013).  The 
duration of the studies ranged from one to 14 years.  The European Society of Cardiology 
recommends utilizing the CHA2DS2-VASc score to estimate stroke risk in patients with AF and 
supports the use of HAS-BLED to evaluate for bleeding risk.  These stroke risk stratification 
schemes for individuals with AF were first developed in 1990 in small cohort studies and were 
further developed and later validated in larger populations (Kirchhof et al., 2016).  The ACC 
compared the CHADS2 score with the CHA2DS2-VAScscore for non-valvular AF and found it 
has a broader score (January et al., 2014).  The AHA/ASA recommended using CHADS2 score 
for patients with AF.  This risk stratification scheme is validated by sufficient evidence from 
randomized control studies (Furie et al., 2012). 
Results of Intervention  
 The two cross sectional studies (Abdul-Rahim et al., 2014; Al-Turaiki et al., 2016;) 
showed a high risk for stroke using the CHA2DS2-VASc with the following scores 5, 2, and > 2. 
A high-risk the CHA2DS2-VASc score is considered > 2.  According to Hart et al. (2007), there 
were 12 trials that randomized placebo or control treatment in individuals who had a history of 
stroke or TIA, and the results showed average stroke rate at 4.1% per year among those on OAC 
and 13% per year among those who were not treated.  The retrospective observational study 
Jacobs et al. (2007) reported 85% of patients ≥ 65 years with chronic nonvalvular AF with low 
hemorrhagic risk were prescribed warfarin.  Those with fall and/or dementia had a 45% mortality 
rate. The retrospective study by Banerjee et al. (2014) showed no statistical difference in the 
number of ischemic strokes or thromboembolism or mortality amongst individuals who had been 
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anticoagulated or nonanticoagulated regardless of the fall history.  The increased risk 
stratification scores were likely due to other comorbidities that influence CHA2DS2-VASc score. 
The retrospective study by Padjen et al. (2013) showed the HAS-BLED score had an 
independent predictive value of symptomatic ICH regardless if treatment for an ischemic stroke 
was conservative or treated with a thrombolysis agent.  A retrospective study by Baker et al. 
(2015) found OAC prescriptions increased from 50.9% to 64.1% in one year.  This increase was 
attributed to the increase in DOAC being prescribed.  
According to a meta-analysis by Hart et al. (2007) dose adjusted warfarin was associated 
with a 64% reduction in stroke among those in six randomized trials with AF.  Unfortunately, no 
stroke risk score was included in these trials.  The survey by Gattellari et al. (2007) reported 
family physicians feared bleeding and personal patient experience with a bleeding.  Next, family 
physicians felt responsible if their patient experienced ICH while OAC for AF.  Physicians chose 
other treatments such as aspirin or clopidogrel instead of warfarin when a patient was 
experiencing bleeding, such as nose bleeds, or had preventable bleeding risks like treated peptic 
ulcers and falls. 
The European stroke prevention guidelines recommend using OAC in men with a 
CHA2DS2-VASc score of 2 or more and a score of 3 or more in women.  The European stroke 
prevention guidelines also recommend against withholding OAC therapy when an individual has 
a high bleeding risk (Kirchhof et al., 2016).  The ACC showed the CHA2DS2-VASc score 
included more risk factors female sex, 65-74 years of age, and vascular disease.  With the  
CHA2DS2-VASc score a woman is not able to achieve score of 0 thus identify higher risk 
females that may have been underscored using the CHADS2 score (January et al., 2014).  The 
AHA/ASA recommended initiating treatment for a CHADS2 score ≥2 (Furie et al., 2012). 
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CHAPTER 3: Theoretical Framework 
 
 The ACE Star Model of Knowledge Transformation (Star Model) has been used in 
clinical and education settings to support evidence-based practice.  This model explains how 
clinical practice guidelines are the solution for moving research findings into everyday practice.  
Healthcare is then improved as new evidence-based knowledge is transformed through the five 
stages of the Kathleen Stevens’ ACE Star Model as cited by Dang et al. (2015).  The five-point 
Star Model represents five different stages of knowledge transformation (Table 2).  
Table 2 
 
ACE Star Model 
Stages of Knowledge Transformation 
Discovery Primary research studies generate new 
knowledge 
 
Evidence Summary A systematic review of all the available 
knowledge 
 
Translation to Guidelines Combine evidence base and expertise 
knowledge to provide recommendations 
 
Practice Integration Factors that affect integration of change to 
reflect the strength of the evidence 
 
Process, Outcome, Evaluation Evidence-based practice is evaluated in regard 
to the patient’s health outcomes, satisfaction, 
and efficacy of care and health policy  
Table 2. ACE Star Model. Adapted from "Models to guide implementation and sustainability of 
evidence-based practice," by Dang et al., 2015, Evidence based practice in nursing & 
healthcare a guide to best practice, 3rd ed., pp. 274- 315. Copyright 2015 by Wolters Kluwer
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The first stage of the Star Model identifies an area of discovery where new knowledge 
generates in primary research studies; in this project, the underuse of OAC in individuals who 
are over the age of 65 with AF.  The second stage, evidence summary, is a systematic review of 
all the literature identifying a range of factors associated with the underuse of OAC in older 
adults with AF.  The third stage combines evidence base and expertise knowledge to provide 
recommendation that translate to guidelines.  Clinical practice guidelines recommend individuals 
with AF who have a CHA2DS2-VASc of > 2 or CHADS2 score ≥2 should be placed on OAC 
provided they do not have a contraindication (January et al., 2014).  
The forth step, practice integration, included factors of change to reflect the strength of 
the evidence.  Integration into practice began in August 2017 with an educational in-service to 
hospitalists and cardiology providers affiliated with CaroMont Regional Medical Center 
(CRMC) that included the CHA2DS2-VASc stroke score, the HAS-BLED bleeding score, and 
their meanings.  A review of clinical practice guidelines for stroke and the use of OAC in older 
adult patients with AF did take place as well as a discussion on patient scenarios that were not 
considered a contraindication for initiating OAC, including falls risk and dementia.  
The fifth stage of the Star Model includes the impact of evidence-based practice 
including the process, outcome, and evaluation.  The process of hospitalist buy in was crucial to 
the project’s success.  Reminding providers of stroke practice guidelines gave support and 
credibility to my project.  Following the educational in-service 100% of those patients who were 
eligible were offered a prescription for OAC.  Indicating that the in-service had a positive impact 
on provider practice and patients’ health outcome in relationship to follow clinical practice  
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guidelines.  Following the implementation period, the project and interactions with staff was 
evaluated.  Over all the project was successful due to providers following practice guidelines and 
offering medication to eligible patients to help reduce a risk factor of stroke. 
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CHAPTER 4: Methodology 
Setting and Participants 
The setting for this DNP project was CaroMont Health a not-for-profit independent 
healthcare system in Gastonia, North Carolina.  This healthcare system includes a 435-bed 
hospital, specialists, primary care offices, urgent care locations, and emergency departments 
throughout the region (http://www.caromonthealth.org/).  The subjects for this DNP project 
included cardiology providers and the primary care providers within the CaroMont Health Care 
System.  These two groups are most often responsible for initiating OAC in the outpatient setting 
following hospital discharge of patients with AF who were admitted for a CVA or TIA.  
Intervention  
An in-service on high stroke risk in the setting of AF and previous TIA/CVA was given to 
the hospitalists and cardiology providers at CaroMont Regional Medical Center (CRMC). 
Information used in the presentation came from evidence-based research articles and clinical 
practice guidelines to provide documentation concerning when to initiate OAC, and to show that 
a fall risk and supervised dementia patients are not contraindications to therapy.  This information 
reinforced the need for change when it came to initiate OAC in older adults with AF.  Information 
provided during the discussion included the CHA2DS2-VASc score and its meaning and how the 
inpatient neurology service at CRMC provide recommendations regarding OAC.  Provider to 
provider follow up education sessions were given to those identified with an eligible patient on 
their service.  The presentation detailed the timing of OAC initiation was dependent on the size of 
a stroke.  If a stroke was small vessel in origin OAC would be initiate
16 
 
in the hospital, those medications typically include apixaban 5mg twice a day depending on renal 
function or warfarin dosed by pharmacy.  If a large vessel stroke were to be identified initiation 
of OAC would be seven to ten days following the stroke.  In patients with large vessel strokes, a 
repeat CT scan of the head may be recommended prior to the initiation of OAC.  An algorithm 
utilizing the HAS-BLED bleeding risk score and CHA2DS2-VASc stroke risk score was provided 
during the presentation to aid in decision-making surrounding OAC (Appendix 1).  The use of 
OAC has been shown to improve patient outcomes by decreasing the risk for embolic stroke or 
ischemic events (Garwood & Corbett, 2008; January et al., 2014; Kirchhof et al., 2017; Sellers & 
Newby, 2011). 
The patient population of interest included those patients 65 years of age and older who 
had been diagnosed with a CVA or TIA while hospitalized at CRMC with a history of AF, were 
not on OAC therapy, and had received a neurology consult during their hospitalization.  The 
hospitalists providing medical management do not typically initiate OAC therapy in the inpatient 
setting; however, they are responsible for providing a hospital discharge summary with specific 
OAC recommendations that primary care providers (PCP) and outpatient cardiology providers 
utilize at follow up appointments.  The hospitalists were asked to include the CHA2DS2-VASc 
score and HAS-BLED scores in the discharge summary along with the recommendation for 
when to start OAC in the outpatient setting based on neurology’s recommendations.  The 
cardiology providers were presented with the same inform as well and reminded that every 
patient should be considered on an individual basis to whether they are eligible for treatment. 
Fall risk and dementia should not be automatic contraindications.  The majority of inpatient 
cardiology providers include a CHA2DS2-VASc scores in their notes on patients with AF.  
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Data Collection 
The EMR was used to identify those patients age 65 or older, admitted to CRMC from 
July 2016 to September 2016 and from July 2017 to September 2017 with a diagnosis of AF and 
CVA/TIA, and who were eligible for OAC.  A review of medical records from the hospital, 
primary care, and cardiology outpatient settings using EPIC identified whether these patients 
received a prescription for an OAC at time of discharge or during a hospital follow up 
appointment.  Addition data used to score the CHA2DS2-VASc score and HAS-BLED score was 
collected (Table 1), in addition to descriptors of the patient population race, body mass index 
(BMI), current smoking, obstructive sleep apnea, dyslipidemia, and a history of neck radiation. 
All patient information, including medical record numbers to allow for tracking 
prescriptions over 30 days, was stored on an encrypted flash drive that was password-protected 
and remained at CRMC at all times.  Once the follow up data was obtained, a random number 
replaced the medical record number to de-identify patient information.  
Analysis Plan  
The principal quantitative outcome was the rate (or percentage) of those patients who 
were eligible for OAC in the outpatient setting and actually received a prescription for an OAC.  
 Due to a small sample size, only descriptive statistics computed using data from each period in 
2016 and 2017 were used to describe these two subsamples.  Standard deviations and means 
were calculated for continuous variables such as age, CHA2DS2-VASc score, and HAS-BLED 
score.  Frequencies and percentages were used to describe categorical variables. 
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CHAPTER 5: Results 
 
A total of 27 patients were included in the analysis, 15 patients in 2016 and 12 patients in 
2017. In 2016, 53% (n=8) received prescriptions for warfarin, 13% received apixaban (n=2), and 
6% received rivaroxaban (n=1).  One patient refused OAC and another patient's family refused 
as the patient transitioned to hospice.  Overall 87% (n=13) patients who were eligible for OAC 
therapy were offered prescriptions by providers.  Two patients were not offered OAC therapy by 
providers due to fall risk and noncompliance.  In 2016, only nine of the 15 providers that 
discharged eligible patients mentioned neurology’s recommendations when to start OAC 
therapy. In 2017 58% (n=7) received prescriptions for apixaban, 33% (n=4) for warfarin, and one 
refused OAC therapy.  Overall, 100% (n=12) patients who were eligible for oral anticoagulation 
therapy were offered prescriptions by providers.  Of those 12 providers, 10 received education 
regarding the stroke and bleeding risk scores.  In 2017, 11 of the 12 providers that discharged 
eligible patients mentioned the stroke/bleeding risk score or neurology's recommendation when 
to start OAC therapy. 
The demographics and clinical characteristics of patients are included in Table 3. One-
hundred percent of those eligible for OAC therapy were Caucasian in 2016 and 2017.  There 
were less females, 67% in 2016 compared to 83% in 2017.  The population was older in 2016 
(mean age 82.2 years, [SD 7.66]) compared to 2017 (mean age 79.7 years [SD 9.86]). Other 
comorbidities such as dementia were equal among the two groups.  Prior falls were more 
common in 2016, 33% compared to 8% in 2017.  Obstructive sleep apnea was present in 6% in 
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2016 compared to 16% in 2017.  No one used tobacco products in 2016 compared to 8% in 2017.  
Forty percent were obese with a BMI greater than 30 in 2016, compared to 58% in 2017. 
 
There were no significant differences observed in the CHA2DS2-VASc scores between the 
two groups (mean score 6.47 [SD 0.51]) compared to the 2017 group (mean score 7 [SD 1.25]). 
There was a higher HAS-BLED score the 2016 patient group (mean score 4 [SD .846]) 
compared to 2017 group (mean score 3.25 [SD 0.62]).  
In 2016, 6% of patients had a prior clinical relevant non-major bleed compared to 16% in 
2017 (Table 4).  Prior to admission, 87% of patients were on an antiplatelet medication in 2016 
compared to 33% in 2017. 
 
  
Table 3 
 
Demographic and Clinical Characteristics 
 2017 2016 
Age years mean (SD) 79.7 (9.86) 82.2 (7.66) 
Female sex, n (% female) 10 (83%) 10 (67%) 
Male sex, n (% male) 2 (17%) 5 (33%) 
Race 12 (100%) Caucasian 15 (100%) Caucasian 
Antiplatelet therapy not on 
admission 
8 (67%) 11 (73%) 
Aspirin 4 (33%) 2 (13%) 
Clopidogrel 0% 0% 
Aspirin &Clopidogrel 0% 1 (6%) 
Medication noncompliance 0% 2 (13%) 
Falls 1 (8%) 5 (33%) 
Dementia 2 (16%) 2 (13%) 
OSA 2 (16%) 1 (6%) 
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Table 4 
 
Stroke and Bleeding Risk Factors (n= 27) 
Stroke Risk Factors 2017 (n=12) 2016 (n=15) 
CHA2DS2-VASc mean  
Standard Deviation (SD) 
Mean 7.08 
SD (0.51) 
Mean 6.47 
SD (1.25) 
Congestive heart failure/LV 
dysfunction 
6 (50%) 9 (60%) 
Hypertension 12 (100%) 13 (87%) 
Age ≥ 75 years 8 (67%) 13 (87%) 
Diabetes mellitus 4 (33%) 7 (47%) 
Stroke/TIA/TE 12 (100%) 15 (100%) 
Vascular disease (prior MI, 
PAD, or aortic plaque) 
4 (33%) 3 (20%) 
Aged 65-74 years 4 (33%) 2 (13%) 
Sex category (female sex) 10 (83%) 10 (67%) 
Bleeding risk factors 2017 (n=12) 2016 (n=12) 
HAS-BLED Mean  
Standard Deviation (SD) 
Mean 3.25 
SD (0.62) 
Mean 4 
SD (0.85) 
Hypertension 12 (100%) 13 (87%) 
Abnormal renal or liver 
function 
 
1 (8.3%) 
 
2 (13%) 
Stroke 12 (100%) 15 (100%) 
Bleeding tendency of 
predisposition 
2 (16%) 1 (6%) 
Labile International 
Normalized Ratio (INR)s (if 
on warfarin) 
0 0 
Drugs 
Aspirin or NSAIDS 
9 (75%) 13 (86%) 
Alcohol excess/abuse 0 0 
 
Table 5 shows stroke and bleeding risk scores for the patients included in this practice 
improvement project.  In 2016, 67% of patient had a higher stroke risk score when compared to 
the bleeding risk score.  Only 33% had a higher bleeding risk score compared to stroke risk 
score.  In 2017, 92% of patients had a higher stroke risk score compared to bleeding risk score.  
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Table 5 
 
Analysis of Bleeding and Stroke Risk  
CHA2DS2-VASc score (stroke risk % per year) 
Has-Bled 
score 
(bleeding risk 
% per year)  
0 
(.84) 
1 
(1.79) 
2 
(3.67) 
3  
(5.75) 
4 
(8.18) 
5 
 
6 
(11.0) 
7 
(11.0) 
8 
(11.0) 
2016  
Patients (15) 
         
0 (1.2)           
1 (2.8)          
2 (3.6)          
3 (6.0)     N=1  N=3 N=1  
4 (9.5)       N=1 N=2 N=2 
5 (12.5)     N=1  N=1 N=2  
6 (12.5)         N=1 
2017 
Patients (12) 
         
0 (1.2)          
1 (2.8)          
2 (3.6)          
3 (6.0)       N=1 N=7 N=2 
4 (9.5)        N=1  
5 (12.6)        N=1  
6. (12.6)          
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CHAPTER 6: Discussion 
The number of eligible patients who were offered prescriptions for OAC increased from 
87% in 2016 to 100% in 2017.  This increase indicates that the intervention resulted in an 
effective practice change among providers.  Of the 12 providers discharging patients with stroke 
and AF, 100% mentioned the stroke risk/bleed risk scores or neurology recommendations in their 
discharge notes.  Two of the providers, a cardiologist and critical care internist, did not receive 
education regarding the implementation project; however, the cardiologist did make mention of 
the stroke risk score in his note and the critical care internist did mention the plan the neurology 
team recommended regarding anticoagulation management.  
Eight of the 15 patients in 2016 were started on warfarin compared to DOACs in three 
patients.  Of the 11 patients who accepted the prescription for OAC therapy in 2017, nine 
received prescriptions for apixaban to fill at discharge, and two received prescriptions to start 
warfarin later.  Physicians are also becoming more familiar with the stroke risk scoring methods 
which may also lead to confidence in prescribing of OAC therapy.  Those on the cardiology 
service are already using the CHA2 DS2-VASc stroke risk score in their notes regarding 
individuals with atrial fibrillation.   
The majority of patients in both groups, 2016 and 2017, were women, while the incident 
of AF is higher in males the risk of death in females with AF is higher (Kirchhof et al., 2016).  
Women are less likely to receive therapy for rate control associated with AF or specialist care.  
They also tend to be older with more comorbidities compared to men (Kirchhof et al., 2016).  
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Using the CHA2 DS2-VASc stroke risk will help to identify more eligible women for 
anticoagulation therapy. In 2016 & 2017, 100% of the patients were Caucasian females.  These 
results did not reflect past epidemiological research in which African American patients are 
known to have a higher incidence of all strokes compared to Caucasians (Meschia et al., 2014). 
Limitations 
 There are several limitations to this project.  The population was drawn from a specific 
institution, resulting in a small sample size.  Similarly, the enrollment period was only three 
months.  Yet another limitation of the project was that it involved only patients who were 
admitted to the hospital and comorbidities may be higher in this population.  There is a 
possibility that eligible patients may have been missed if the hospital neurology team was not 
consulted during their hospitalization.  Also, if coding for a stroke or TIA was not listed in the 
EMR, potential patients may have been missed.  Stroke and bleeding risk score education only 
encompassed hospitalists working day shift.  The intensive care internists and nocturnist 
hospitalists were not educated regarding the practice improvement due to low expectations that 
they would write a discharge summary.  Lastly, most stroke patients in this project had small 
vessel strokes thus, OACs were started in the hospital setting or on day of discharge rather than 
waiting a week and initiating in the outpatient setting.  The number of providers offering OAC 
prescriptions may not have been as high in the outpatient setting because of this.  
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CHAPTER 7: Implications for Practice 
Practice improvement for correcting the underuse of OAC was seen following the 
discussion with providers regarding practice guidelines, stroke and bleeding risk scores, an 
anticoagulant algorithm (Appendix 1), and recommendations made by neurology.  The number 
of patients discharged with prescriptions for OAC increased.  By using the Anticoagulant 
Algorithm (Appendix 1), providers can identify who needs therapy.  Other providers in the 
health care system such as intensivists, nocturnal hospitalists, and primary care providers would 
benefit from this education.  Continued effort by those discharging patients to include 
neurology’s recommendations when to initiate OAC therapy on a specific date, dosing of 
medications, stroke risk score, and bleeding risk score in their discharge summary provides 
support to those in the outpatient setting initiating OAC and to those in the inpatient setting to 
initiate during the hospitalization or at discharge when appropriate.  Recognizing high risk stroke 
patients with non-AF by using the CHA2 DS2-VASc would increase the number of patients 
prescribed OAC and improve cardioembolic stroke protection (Padjen et al., 2013; Hart, Pearce, 
& Aguilar, 2007).  
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CHAPTER 8: Conclusion 
Following the education about the underuse of OAC therapy and practice guidelines there 
was an increase in prescribing OAC at time of discharge in patients with AF who had a stroke, 
rather than leaving it up to outpatient providers.  Some hospitalists have since adopted the stroke 
risk scores as a part of their history and physical templates for stroke patients.  While the sample 
size was small in this project the was potential for significant improvement in health outcomes. 
The risk for bleeding versus risk for stroke should be evaluated on an individual basis and the 
risk versus the benefits should be discussed with each patient.  Including stroke and bleeding risk 
scores in hospital notes and discharge summaries identify those patients who are at a high risk 
for a stroke and to support the use of OAC. 
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Appendix: Anticoagulant Algorithm 
 
 
  
Determine stroke risk 
using CHA2DS2-VASc 
score 
If the CHA2DS2-
VASc score is > 2, 
determine the 
bleeding risk using 
the HAS-BLED 
score. 
If the HAS-BLED score is ≥ 3, 
modify bleeding risk factors if 
possible, and then consider 
prescribing an OAC
VKA or DOAC
If the HAS-BLED score is < 
3, (low risk for bleeding 
complication) recommend 
OAC.
VKA or DOAC
CHA2DS2-VASc score  
0 for male and 1 
female no OAC 
needed
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